| Literature DB >> 32487575 |
Jun Wang1, Shulan Li1, Bingshu He2.
Abstract
INTRODUCTION: Eco-directed sustainable prescribing (EDSP) is an effective upstream way to reduce the environmental footprints of active pharmaceutical ingredients (APIs), a kind of emerging contaminants, from the patients' excretion. EDSP is one of the key steps in the programme of ecopharmacovigilance (EPV), a drug administration route on API pollution.Entities:
Keywords: Health & safety; medical education & training; public health; quality in health care
Mesh:
Substances:
Year: 2020 PMID: 32487575 PMCID: PMC7265008 DOI: 10.1136/bmjopen-2019-035502
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Demographic information and knowledge score of Chinese physicians participating in the study (n=262)
| Participant characteristics | Respondents no. (%) |
| Gender | |
| Male | 124 (47) |
| Female | 139 (53) |
| Age | |
| 20–40 years | 125 (48) |
| >40 years | 137 (52) |
| Postgraduate training | |
| Yes | 170 (65) |
| No | 92 (35) |
| Job category | |
| Internal medicine | 102 (39) |
| Surgery | 98 (37) |
| Others | 62 (24) |
| Years of experience | |
| ≤10 | 92 (35) |
| 11–20 | 96 (37) |
| >20 | 74 (28) |
Chinese physicians’ perceptions toward API pollution in environment and EPV (n=262)
| Survey question/statement | Respondents no. (%) | ||||
| Strongly agree | Agree | Undecided | Disagree | Strongly disagree | |
| Q1: APIs used in healthcare practices could finally enter into the environment. | 96 (37) | 113 (43) | 45 (17) | 8 (3) | 0 (0) |
| Q2: API residues in environment could cause adverse effects on ecosystem, wildlife species, even human beings. | 126 (48) | 108 (41) | 26 (10) | 2 (1) | 0 (0) |
| Q3: It is necessary to minimise the entrance of APIs into the environment. | 104 (40) | 125 (48) | 31 (12) | 2 (1) | 0 (0) |
| Q4: The control of API pollution is none of my business, because it should be the responsibility of environmental experts and regulators. | 5 (2) | 6 (2) | 73 (28) | 80 (31) | 98 (37) |
| Q5: API pollution could be ultimately traced back to the use of medications in healthcare practices. | 113 (43) | 96 (37) | 50 (19) | 3 (1) | 0 (0) |
| Q6: If there is an upstream intervention for controlling API entry to the environment, I would endorse it, and be very pleased to participate in its implementation. | 68 (26) | 99 (38) | 94 (36) | 1 (0) | 0 (0) |
| Q7: Based on the description of EPV given on the first page of this questionnaire, I think EPV is an effective tool to control API entry to the environment. | 83 (32) | 74 (28) | 98 (37) | 5 (2) | 2 (1) |
APIs, active pharmaceutical ingredients; EPV, ecopharmacovigilance.
Assessment of Chinese physicians’ perceptions and attitudes toward EDSP (n=262)
| Survey question/statement | Response | Respondents no. (%) |
| Q1: At present, the aspects regarding medicines affecting my prescription decision include:* | Efficacy | 262 (100) |
| Safety | 258 (98) | |
| Cost and economy | 246 (94) | |
| Convenience | 188 (72) | |
| Pharmacokinetics | 57 (22) | |
| Marketing and promoting | 139 (53) | |
| Environmental impacts | 0 (0) | |
| Q2: As prescribers, physicians bear a responsibility for reducing API releases to environment. | Strongly agree | 86 (33) |
| Agree | 83 (32) | |
| Undecided | 81 (31) | |
| Disagree | 12 (5) | |
| Strongly disagree | 0 (0) | |
| Q3: Previous to this survey, I have heard of EDSP. | Yes | 260 (99) |
| No | 2 (1) | |
| Q4: According to the description on the basic concept of EDSP provided on the first page of this questionnaire, I think EDSP is an effective tool to control the entrance of APIs into the environment. | Strongly agree | 54 (21) |
| Agree | 96 (37) | |
| Undecided | 101 (39) | |
| Disagree | 9 (3) | |
| Strongly disagree | 2 (1) | |
| Q5: I think the benefits of | Reducing the environmental loading of API residues from patients’ excretions. | 257 (98) |
| Eliminating the subsequent need and cost for disposal of pharmaceutical leftovers | 240 (92) | |
| Reducing healthcare expenditures for patients. | 104 (40) | |
| Improving therapeutic efficacy | 75 (29) | |
| Protecting public health by unintended poisonings by drugs (especially infants, toddlers and children) resulted from inappropriate storage or disposal. | 238 (91) | |
| Reducing drug diversion and the profound problems with attendant abuse of certain drugs and misuse of others. | 215 (82) | |
| Improving public trust—by reducing hidden and unwelcomed exposure of humans to trace levels of numerous APIs | 242 (92) | |
| Improving patient/physician communication. | 89 (34) | |
| Q6: My concerns regarding the | It can not achieve ideal therapeutic efficacy, and might delay treatment. | 262 (100) |
| The lowest effective dose with environmental safety is not certain and available. | 259 (99) | |
| It is a new prescribing concept, therefore, a long time will be taken to popularise it in clinical practice. | 207 (79) | |
| It will change my prescribing habits, thus is too troublesome. | 55 (21) | |
| Q7: It is necessary to emphasise on the metabolism and excretion of drugs rather than the initially ingested dose by the patient, because the emission of APIs into the environment | Strongly agree | 79 (30) |
| Agree | 123 (45) | |
| Undecided | 48 (18) | |
| Disagree | 11 (4) | |
| Strongly disagree | 1 (0) | |
| Q8: My concerns regarding the | It can not achieve ideal therapeutic efficacy, and might delay treatment. | 35 (13) |
| Under the EDSP design, drug evaluation based on the excretion profile and pharmacokinetics is too complicated and professional. | 219 (84) | |
| There is no available accurate data on the excretion profile and pharmacokinetics of drugs. | 190 (73) | |
| It is a new prescribing concept, therefore, a long time will be taken to popularise it in clinical practice. | 211 (81) | |
| It will change my prescribing habits, thus is too troublesome. | 62 (24) | |
| Q9: My self-satisfaction with knowledge on EDSP. | Agree | 0 (0) |
| Disagree | 262 (100) | |
| Q10: My confidence toward EDSP. | Agree | 0 (0) |
| Disagree | 262 (100) | |
| Q11: For now, the EDSP behaviour that I want to choose first is: | None. I will take a wait-and-see approach. | 134 (51) |
| I will promote rational prescribing at precise doses, avoid overprescribing and misprescribing. | 121 (46) | |
| I will implement the low-dose prescribing. | 3 (1) | |
| I will prescribe drugs possessing environment-friendly excretion profiles as much as possible. | 4 (2) | |
| Q12: I think the most major perceived barrier to the effective implementation of EDSP under the perspective of EPV in China is: | Poor awareness of EDSP and EPV. | 101 (39) |
| Lack of an administrative framework for EDSP under the perspective of EPV. | 50 (19) | |
| Lack of available data related to EDSP under the perspective of EPV. | 96 (37) | |
| It conflicts with long-accepted prescribing guidelines. | 15 (6) | |
| Q13: I am very pleased to participate in EDSP activities in my future practice if it is successfully translated into clinical treatment. | Strongly agree | 85 (32) |
| Agree | 121 (46) | |
| Undecided | 53 (20) | |
| Disagree | 3 (1) | |
| Strongly disagree | 0 (0) |
*Multiple responses were permitted, percentages do not add to 100%.
APIs, active pharmaceutical ingredients; EDSP, eco-directed sustainable prescribing; EPV, ecopharmacovigilance.